T-DM1 show overall survival advantage as Roche/Genentech make US and EU filings
This article was originally published in Scrip
Roche and its cancer specialist unit Genentech have announced that following the demonstration of an overall survival benefit in the Phase III EMILIA study, they will file for US and EU regulatory approval of the antibody-drug conjugate T-DM1 (trastuzumab emtansine). The filing had been widely expected since the antibody-drug conjugate – developed with cytotoxic and conjugation technology developed by Waltham, Massachusetts-based Immunogen - generated impressive progression-free survival results in EMILIA. Analysts are anticipating approval as early as the first quarter of 2013.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.